(Sharecast News) - The chief executive of Ozempic-maker Novo Nordisk is to leave the company, it was announced on Friday, just days after the Danish biotech slashed its full-year forecasts.
The pioneering obesity specialist, which also makes Wegovy, said Lars Fruergaard Jorgensen was stepping down by mutual agreement after eight years...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE